Anti-BCMA heavy chain-only antibodies
Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
1. A heavy chain-only antibody binding to human B-Cell Maturation Antigen (BCMA) comprising a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 9, and a CDR3 sequence of SEQ ID NO: 13.
2. The heavy chain-only antibody of claim 1 , wherein said CDR1, CDR2, and CDR3 sequences are present in a human framework.
3. The heavy chain-only antibody of claim 1 further comprising a heavy chain constant region sequence in the absence of a CH1 sequence.
4. The heavy chain-only antibody of claim 1 , comprising a heavy chain variable region having at least 95% sequence identity to SEQ ID NO: 30.
5. The heavy chain-only antibody of claim 4 comprising a heavy chain variable region sequence comprising SEQ ID NO: 30.
6. A heavy chain-only antibody binding to human B-Cell Maturation Antigen (BCMA) comprising a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 9, and a CDR3 sequence of SEQ ID NO: 13 in a human VH framework.
7. The heavy chain-only antibody of claim 6 , further comprising a heavy chain constant region sequence in the absence of a CH1 sequence.
8. The heavy chain-only antibody of claim 7 , which is multi-specific.
9. The heavy chain-only antibody of claim 8 , which is bispecific.
10. The heavy chain-only antibody of claim 8 , having binding affinity to an effector cell.
11. The heavy chain-only antibody of claim 8 , having binding affinity to a T-cell antigen.
12. The heavy chain-only antibody of claim 11 , having binding affinity to CD3.
13. A pharmaceutical composition comprising a heavy chain-only antibody of claim 7 .